Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)

Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)

Abstract O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and its subsequent loss of protein expression has been identified to have a variable impact on clinical outcome of glioma patients indicated for chemotherapy with alkylating agents (Temozolomide). This study investigated met...

Full description

Bibliographic Details
Main Authors: Arshad A. Pandith, Iqbal Qasim, Wani Zahoor, Parveen Shah, Abdul R. Bhat, Dheera Sanadhya, Zafar A. Shah, Niyaz A. Naikoo
Format: Article
Language:English
Published: Nature Publishing Group 2018-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-018-25169-2

Internet

https://doi.org/10.1038/s41598-018-25169-2

Similar Items